Company Insights

BWAY customer relationships

Explore interactive graphBrowse insights index
BWAY customer relationship map

BrainsWay (BWAY): payer wins are converting clinical innovation into commercial traction

BrainsWay Ltd. sells non‑invasive neuromodulation systems and monetizes through device sales, consumable/procedure revenue and clinic partnerships for its Deep TMS™ and accelerated SWIFT™ protocols; recent payer policy expansions materially lower reimbursement barriers and accelerate addressable patient volume. Investors should value BrainsWay as a commercial‑stage medical device firm transitioning from clinical proof into scalable revenue growth as major insurers broaden coverage for adolescent and adult major depressive disorder (MDD).
For a consolidated view of customer relationships and coverage momentum, visit https://nullexposure.com/.

Payers are the growth engine — why coverage decisions matter now

BrainsWay’s commercial model depends on insurer medical policies and network acceptance as much as device performance. Coverage expansions translate directly into higher utilization of clinic services and faster installed‑base monetization because insurers determine patient access and reimbursement for Deep TMS courses. Recent headlines show a steady cadence of policy updates across large national and regional payers — an outcome that increases predictability of procedure revenue while reducing sales friction for clinics deploying BrainsWay systems.

Operationally, this produces several company‑level signals:

  • Contracting posture: BrainsWay is operating in a favorable contracting environment as multiple payers adopt or extend coverage for Deep TMS, reducing prior‑authorization friction and shortening sales cycles for provider customers.
  • Concentration: Coverage is diversifying across national payers and regional Blues, lowering single‑payer revenue concentration risk compared with earlier stages of commercialization.
  • Criticality: Deep TMS is becoming a reimbursed alternative for treatment‑resistant and adolescent MDD, increasing BrainsWay’s relevance to behavioral‑health treatment pathways and to clinics seeking non‑pharmacologic options.
  • Maturity: The company is firmly commercial‑stage—coverage wins and clinical partnerships indicate a shift from purely evidence accumulation to scaled commercial execution.

If you want a concise repository of these payer relationships and how they impact commercial risk, check https://nullexposure.com/ for our full coverage maps.

The relationships that matter — payer and partner roll‑call

Below are every customer and partner name cited in the public releases tied to BrainsWay’s coverage announcements. Each entry is a plain‑English capsule and a direct source for verification.

Optum Behavioral Health / Optum (UnitedHealth Group, UNH)

Optum Behavioral Health expanded its medical policy to cover Deep TMS™ for adolescents aged 15 and older with MDD, broadening access across a very large member base. Source: Globenewswire and TradingView coverage of the company release (FY2025) — https://www.globenewswire.com/news-release/2025/12/22/3209133/0/en/BrainsWay-Reports-Expansion-of-Adolescent-Depression-Coverage-Applicable-to-Deep-TMS.html and https://www.tradingview.com/news/zacks:56b84b7f9094b:0-bway-shares-gain-on-optum-expanding-deep-tms-coverage-for-teens/ (FY2025).

Highmark Blue Cross Blue Shield / Highmark

Highmark released a draft medical policy expanding coverage to adolescents and adults with MDD treated with BrainsWay’s accelerated Deep TMS protocol, indicating state‑level Blues alignment. Source: Company filing and Globenewswire (FY2026) — https://www.stocktitan.net/sec-filings/BWAY/6-k-brainsway-ltd-current-report-foreign-issuer-32f9c2b82fdf.html and https://www.globenewswire.com/news-release/2026/01/21/3222675/0/en/BrainsWay-Announces-Draft-Coverage-Policy-from-Highmark-for-Accelerated-Deep-TMS.html (FY2026).

Premera Blue Cross Blue Shield / Premera

Premera adopted a final medical policy expanding coverage for BrainsWay’s accelerated SWIFT™ Deep TMS protocol to patients ages 15 and older, opening Washington and Alaska markets. Source: Globenewswire and StockTitan reporting (FY2026) — https://www.globenewswire.com/news-release/2026/01/07/3214432/0/en/BrainsWay-Announces-First-Coverage-Policy-for-Accelerated-Deep-TMS.html and https://www.stocktitan.net/news/BWAY/brains-way-announces-first-coverage-policy-for-accelerated-deep-eg93e0y4uxay.html (FY2026).

Evernorth Health Services / Evernorth Behavioral Health (Cigna/Evernorth)

Evernorth expanded coverage and removed prior‑authorization requirements for Deep TMS, a meaningful administrative simplification for providers and patients. Source: Globenewswire and StockTitan (FY2025–FY2026) — https://www.globenewswire.com/news-release/2025/12/22/3209133/0/en/BrainsWay-Reports-Expansion-of-Adolescent-Depression-Coverage-Applicable-to-Deep-TMS.html and https://www.stocktitan.net/news/BWAY/landmark-data-validate-brains-way-s-swifttm-deep-tms-beginning-a-new-dvutkbr8jsnv.html (FY2026).

CVS/Aetna

CVS/Aetna is listed among major insurers that already cover Deep TMS for adolescents with MDD, indicating national commercial payer acceptance. Source: Globenewswire and Yahoo! Finance reporting (FY2025) — https://www.globenewswire.com/news-release/2025/12/22/3209133/0/en/BrainsWay-Reports-Expansion-of-Adolescent-Depression-Coverage-Applicable-to-Deep-TMS.html and https://sg.finance.yahoo.com/news/bway-shares-gain-optum-expanding-170700463.html (FY2025).

Health Care Service Corporation (HCSC)

HCSC is cited as one of several large Blues already covering Deep TMS for adolescents, signaling Midwest regional acceptance. Source: Globenewswire (FY2025) — https://www.globenewswire.com/news-release/2025/12/22/3209133/0/en/BrainsWay-Reports-Expansion-of-Adolescent-Depression-Coverage-Applicable-to-Deep-TMS.html (FY2025).

Blue Cross Blue Shield of Michigan

BCBS Michigan is named among Blues plans covering adolescent Deep TMS, supporting statewide access in Michigan. Source: Globenewswire and market coverage (FY2025) — https://www.globenewswire.com/news-release/2025/12/22/3209133/0/en/BrainsWay-Reports-Expansion-of-Adolescent-Depression-Coverage-Applicable-to-Deep-TMS.html (FY2025).

Blue Cross Blue Shield of North Carolina

BCBS North Carolina is listed among Blues covering Deep TMS for adolescents, expanding regional payer support. Source: TradingView and Globenewswire (FY2025) — https://www.tradingview.com/news/zacks:56b84b7f9094b:0-bway-shares-gain-on-optum-expanding-deep-tms-coverage-for-teens/ and https://www.globenewswire.com/news-release/2025/12/22/3209133/0/en/BrainsWay-Reports-Expansion-of-Adolescent-Depression-Coverage-Applicable-to-Deep-TMS.html (FY2025).

Florida Blue

Florida Blue is included in the list of Blues plans that cover Deep TMS for adolescent MDD, extending coverage into a major state market. Source: TradingView / Globenewswire (FY2025) — https://www.tradingview.com/news/zacks:56b84b7f9094b:0-bway-shares-gain-on-optum-expanding-deep-tms-coverage-for-teens/ (FY2025).

PacificSource Health Plans

PacificSource is cited among regional plans already covering adolescent Deep TMS, signaling additional West Coast/regional footprint. Source: Globenewswire and StockTitan reporting (FY2025) — https://www.globenewswire.com/news-release/2025/12/22/3209133/0/en/BrainsWay-Reports-Expansion-of-Adolescent-Depression-Coverage-Applicable-to-Deep-TMS.html (FY2025).

Regence

Regence appears in multiple summaries as a Blue plan that covers Deep TMS for adolescents, reinforcing Pacific Northwest acceptance. Source: Globenewswire and TradingView summaries (FY2025) — https://www.globenewswire.com/news-release/2025/12/22/3209133/0/en/BrainsWay-Reports-Expansion-of-Adolescent-Depression-Coverage-Applicable-to-Deep-TMS.html and https://www.tradingview.com/news/zacks:56b84b7f9094b:0-bway-shares-gain-on-optum-expanding-deep-tms-coverage-for-teens/ (FY2025).

Medi‑Cal

California’s Medi‑Cal is listed among payers covering adolescent Deep TMS, an important sign for public program access. Source: Globenewswire (FY2025) — https://www.globenewswire.com/news-release/2025/12/22/3209133/0/en/BrainsWay-Reports-Expansion-of-Adolescent-Depression-Coverage-Applicable-to-Deep-TMS.html (FY2025).

TRICARE

TRICARE appears on the list of payers covering Deep TMS for adolescents, indicating access through military and veteran care programs. Source: Globenewswire (FY2025) — https://www.globenewswire.com/news-release/2025/12/22/3209133/0/en/BrainsWay-Reports-Expansion-of-Adolescent-Depression-Coverage-Applicable-to-Deep-TMS.html (FY2025).

BrainStim Health Inc.

BrainsWay announced a minority‑stake investment in BrainStim, a Canadian provider and longtime partner, aligning clinical channel growth with capital support. Source: Globenewswire and StockTitan (FY2026) — https://www.globenewswire.com/news-release/2026/02/19/3240982/0/en/BrainsWay-Announces-New-Minority-Stake-Investment-in-Canadian-Provider-BrainStim-Health-Inc.html and https://www.stocktitan.net/news/BWAY/brains-way-announces-new-minority-stake-investment-in-canadian-ld5j0id2u7h0.html (FY2026).

How investors should read these relationships

The pattern is clear: multiple national and regional payers are converging on coverage for Deep TMS, and administrative barriers like prior authorization are being relaxed in some networks. That combination reduces sales friction and improves predictable revenue realization from procedures and consumables. At the same time, BrainsWay remains exposed to the usual healthcare risks: payer policy reversals, clinic adoption cycles and competitive technologies.

For investors evaluating customer concentration and commercial durability, the expanded payer list is a positive signal that reimbursement risk is declining and addressable market is growing. For operator due diligence, these relationships indicate faster clinic onboarding and improved cash flow conversion from installed systems.

If you want a single place to track these payer events and derive customer concentration metrics, visit https://nullexposure.com/ to explore our coverage tools.

Final takeaways and action steps

  • Coverage momentum is a structural commercial catalyst for BrainsWay: payer policy wins increase utilization and shorten sales cycles.
  • Risk remains operational — adoption at the clinic level and competitor dynamics will determine the slope of revenue scaling.
  • Investor action: monitor sequential procedure volumes, gross margin trends on consumables and any changes to payer policies that could alter access.

To follow updates and see how these payer relationships evolve in real time, go to https://nullexposure.com/.